PipelineReview.com, Oct. 24, 2006http://www.pipelinereview.com/joomla/content/view/7469/109/ Sepracor Inc. today announced that it presented data from a Phase   III pivotal trial at the annual meeting of the American College of Chest Physicians (ACCP), in Salt Lake City. Results of a double-blind, randomized, placebo-controlled study … found rapid bronchodilation and maintenance improvement, providing beneficial therapeutic effects for patients with COPD, according to William J. Calhoun M.D., Sealy and Smith Distinguished Professor of Internal Medicine; Director, Division of Allergy, Pulmonary, Immunology, CCM, and Sleep at the University of Texas Medical Branch, Galveston, Texas.